David Erlinge1, Sasha Koul2, Peter Eriksson3, Fredrik Scherstén2, Elmir Omerovic4, Rikard Linder5, Olof Petter Östlund6, Lars Wallentin6, Ole Fröbert7, Stefan James6. 1. Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden. Electronic address: david.erlinge@med.lu.se. 2. Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden. 3. Department of Cardiology, Umeå University, Umeå, Sweden. 4. Department of Cardiology, Sahlgrenska University, Gothenburg, Sweden. 5. Department of Cardiology, Danderyd, Karolinska University, Stockholm, Sweden. 6. Department of Medical Sciences, and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. 7. Department of Cardiology, Faculty of Health, Örebro University, Sweden.
Abstract
BACKGROUND: The optimal anticoagulant for patients with acute coronary syndrome treated withpercutaneous coronary intervention (PCI) has not been validated in current practice of radial approach and pretreatment with potent P2Y12 inhibitors. Several studies have indicated increased bleeding rate and, in some instances, even increased mortality by the routine use of heparin and glycoprotein IIb/IIIa inhibitors compared to bivalirudin. Direct comparison of bivalirudin versus heparin alone has yielded contradictory results depending on study designs. METHODS/ DESIGN: The VALIDATE-SWEDEHEART trial is a multicenter, prospective, randomized, registry-based, controlled, and open-label clinical trial in patients with ST-segment elevation myocardial infarction (STEMI) or non-STEMI undergoing PCI pretreated withticagrelor, prasugrel, or cangrelor. We hypothesize that bivalirudin is superior to heparin alone in reducing death, myocardial infarction, and major bleeding events at 180 days (primary end point). The trial will enroll 3,000 patients with STEMI and 3,000 patients with non-STEMI undergoing PCI. The trial will use a hybrid registry-based randomized clinical trial design where inclusion, randomization, and baseline data collection are performed using The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry. The primary composite end point (death, myocardial infarction, or major bleeding events at 180 days) will be identified through active screening after 7 and 180 days and adjudicated by a blinded central end point committee. Secondary end points and long-term outcomes will be recorded from national registries. CONCLUSION: The VALIDATE-SWEDEHEART trial is founded on a nationwide clinical registry and uses a hybrid registry-based randomized clinical trial (RRCT) design methodology to evaluate efficacy and safety of bivalirudin as compared to heparin alone for acute coronary syndrome, in a large population receiving contemporary recommended therapies including predominantly radial invasive approach and pretreatment with potent P2Y12 inhibitors.
RCT Entities:
BACKGROUND: The optimal anticoagulant for patients with acute coronary syndrome treated with percutaneous coronary intervention (PCI) has not been validated in current practice of radial approach and pretreatment with potent P2Y12 inhibitors. Several studies have indicated increased bleeding rate and, in some instances, even increased mortality by the routine use of heparin and glycoprotein IIb/IIIa inhibitors compared to bivalirudin. Direct comparison of bivalirudin versus heparin alone has yielded contradictory results depending on study designs. METHODS/ DESIGN: The VALIDATE-SWEDEHEART trial is a multicenter, prospective, randomized, registry-based, controlled, and open-label clinical trial in patients with ST-segment elevation myocardial infarction (STEMI) or non-STEMI undergoing PCI pretreated with ticagrelor, prasugrel, or cangrelor. We hypothesize that bivalirudin is superior to heparin alone in reducing death, myocardial infarction, and major bleeding events at 180 days (primary end point). The trial will enroll 3,000 patients with STEMI and 3,000 patients with non-STEMI undergoing PCI. The trial will use a hybrid registry-based randomized clinical trial design where inclusion, randomization, and baseline data collection are performed using The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry. The primary composite end point (death, myocardial infarction, or major bleeding events at 180 days) will be identified through active screening after 7 and 180 days and adjudicated by a blinded central end point committee. Secondary end points and long-term outcomes will be recorded from national registries. CONCLUSION: The VALIDATE-SWEDEHEART trial is founded on a nationwide clinical registry and uses a hybrid registry-based randomized clinical trial (RRCT) design methodology to evaluate efficacy and safety of bivalirudin as compared to heparin alone for acute coronary syndrome, in a large population receiving contemporary recommended therapies including predominantly radial invasive approach and pretreatment with potent P2Y12 inhibitors.
Authors: Bahar Behrouzi; Maria Viviana Araujo Campoverde; Kyle Liang; H Keipp Talbot; Isaac I Bogoch; Allison McGeer; Ole Fröbert; Mark Loeb; Orly Vardeny; Scott D Solomon; Jacob A Udell Journal: J Am Coll Cardiol Date: 2020-10-13 Impact factor: 24.094
Authors: Linda Kwakkenbos; Mahrukh Imran; Stephen J McCall; Kimberly A McCord; Ole Fröbert; Lars G Hemkens; Merrick Zwarenstein; Clare Relton; Danielle B Rice; Sinéad M Langan; Eric I Benchimol; Lehana Thabane; Marion K Campbell; Margaret Sampson; David Erlinge; Helena M Verkooijen; David Moher; Isabelle Boutron; Philippe Ravaud; Jon Nicholl; Rudolf Uher; Maureen Sauvé; John Fletcher; David Torgerson; Chris Gale; Edmund Juszczak; Brett D Thombs Journal: BMJ Date: 2021-04-29
Authors: Christian Dworeck; Björn Redfors; Oskar Angerås; Inger Haraldsson; Jacob Odenstedt; Dan Ioanes; Petur Petursson; Sebastian Völz; Jonas Persson; Sasha Koul; Dimitrios Venetsanos; Anders Ulvenstam; Robin Hofmann; Jens Jensen; Per Albertsson; Truls Råmunddal; Anders Jeppsson; David Erlinge; Elmir Omerovic Journal: JAMA Netw Open Date: 2020-10-01
Authors: Gordon Chu; Jaap Seelig; Emmy M Trinks-Roerdink; Anouk P van Alem; Marco Alings; Bart van den Bemt; Lucas Va Boersma; Marc A Brouwer; Suzanne C Cannegieter; Hugo Ten Cate; Charles Jhj Kirchhof; Harry Jgm Crijns; Ewoud J van Dijk; Arif Elvan; Isabelle C van Gelder; Joris R de Groot; Frank R den Hartog; Jonas Ssg de Jong; Sylvie de Jong; Frederikus A Klok; Timo Lenderink; Justin G Luermans; Joan G Meeder; Ron Pisters; Peter Polak; Michiel Rienstra; Frans Smeets; Giovanni Jm Tahapary; Luc Theunissen; Robert G Tieleman; Serge A Trines; Pepijn van der Voort; Geert-Jan Geersing; Frans H Rutten; Martin Ew Hemels; Menno V Huisman Journal: BMJ Open Date: 2020-08-24 Impact factor: 2.692
Authors: Amir Faour; Nicholas Collins; Trent Williams; Arshad Khan; Craig P Juergens; Sidney Lo; Darren L Walters; Derek P Chew; John K French Journal: PLoS One Date: 2021-10-26 Impact factor: 3.240